Abstract
The rate of hepatitis C virus (HCV) related liver cirrhosis and subsequent cancer development is increasing and raising the risk of related mortality and morbidity. To address this issue, we aimed to develop a prognostic index that can be used to stratify patients for risk of disease progression. This index was developed in part by using a gene signature test implemented in a clinically applicable digital transcript counting platform (NanoString nCounter system). A cohort of 145 U.S. patients with HCV-related early-stage cirrhosis was analyzed by using the assay. This dataset (GEO accession number GPL17230) provides information of expression levels of the prognostic genes in the cohort.
Original language | English (US) |
---|---|
Pages (from-to) | 361-362 |
Number of pages | 2 |
Journal | Genomics Data |
Volume | 2 |
DOIs | |
State | Published - 2014 |
Externally published | Yes |
Keywords
- Cirrhosis
- Gene expression
- Hepatitis C
- NanoString nCounter
- Prognostic
ASJC Scopus subject areas
- Biotechnology
- Biochemistry
- Molecular Medicine
- Genetics